(NewsDirect)
NuGen Medical Devices CEO Ian Heynenjoined Steve Darling from Proactive to discuss his appointment andshare some exciting news regarding the company's needle-freeInsuJet injection device.
Heynenbrings a wealth of experience to his role as CEO, with a strong trackrecord in the med-tech industry. He has a history of leadership intechnology-driven organizations, ranging from operational start-ups toturnaround situations and high-growth companies.
Heynen's expertise includes managingP&Ls for both North American and international businesses, withmulti-site divisions and gross revenues exceeding $600 million. He isknown for driving growth through product innovation and internationalexpansion in both startup and multinational firms.
In addition to his appointment, Heynenalso shared a significant achievement for NuGen Medical Devices. TheMexican government has completed the registration of NuGen'sneedle-free InsuJet injection device as a medical device for salethroughout the country.
Furthermore,NuGen has a distribution agreement in place with Science-Link, aimingto sell approximately 5,000 needle-free injectors in 2024.
Looking to 2024, Heynen outlinedNuGen's plans for both geographical market expansion and astrategic shift towards collaborating with pharma companies andhealthcare systems. The goal is to broaden the technology'srecognition and accessibility, particularly in Canada, the US, the UK,and additional EU markets.
The interview showcases NuGen'scommitment to revolutionizing medical device technology and improvingpatient experiences worldwide.
ContactDetails
Proactive Investors
+1 604-688-8158
na-editorial@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.